Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY:ABBV)

206.27 -3.25 (-1.55%)
Official Closing Price Updated: 7:00 PM EDT, Apr 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2 3 4 5 6 7 8 9
...
76 77 Next >
Tech Stocks Rally, S&P 500 Flirts With Records, Gold Extends All-Time Highs: What's Driving Markets Friday?
Major stock indices have completed their recovery following Monday's sharp drop, buoyed by tech stocks rallying on the back of solid earnings and positive macroeconomic data. The S&P 500 index stands... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why AbbVie Stock Is Jumping Today
Via The Motley Fool
AbbVie Investors Trigger Trend-Following Signal: Time to Load Up
AbbVie is on track to sustain growth in the wake of Humira's patent cliff and the forecasts are too low. Investors can look forward to an upgrade cycle in 2025. 
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property
$100 Invested In AbbVie 5 Years Ago Would Be Worth This Much Today
Via Benzinga
A Glimpse Into The Expert Outlook On AbbVie Through 15 Analysts
Via Benzinga
$1000 Invested In AbbVie 5 Years Ago Would Be Worth This Much Today
Via Benzinga
AbbVie Stock Nears 3-Month High on Q4 Beat As Immunology Growth Eases Humira Slump: Retail Mood Brightens
The company raised its long-term sales outlook for Skyrizi and Rinvoq, now expecting combined revenue of about $24 billion in 2025. 
Via Stocktwits
Charter Communications Posts Upbeat Earnings, Joins Atlassian, SkyWest, Eastman Chemical, AbbVie And Other Big Stocks Moving Higher On Friday
Via Benzinga
AbbVie Jumps After Q4 Earnings Beat, Skyrizi And Rinvoq Boom Offsets Humira Decline
AbbVie Q4 earnings beat estimates, driven by strong sales of Skyrizi and Rinvoq, with an updated 2027 combined revenue forecast of $31 billion for both drugs. 
Via Benzinga
Topics Earnings
Exposures Financial
5 Top Stocks to Buy in February 2025
All of them have great upside. 
Via The Motley Fool
Unpacking the Latest Options Trading Trends in AbbVie
Via Benzinga
Friday's pre-market session: top gainers and losers in the S&P500 index
Get insights into the top gainers and losers in the S&P500 index of Friday's pre-market session. 
Via Chartmill
AbbVie Jumps After Its Powerhouses, Skyrizi And Rinvoq, Continued To Dominate
The company now expects Skyrizi and Rinvoq to bring in $31 billion in combined sales in 2027. 
Via Investor's Business Daily
US Stock Futures Climb After Apple Beats Q4 Expectations: Expert Says Tech Stocks Hold Above Key Level Despite DeepSeek Impact
US stock futures climbed on Friday, pointing to a third straight week of gains fueled by strong corporate earnings. 
Via Benzinga
Earnings Scheduled For January 31, 2025
Via Benzinga
AbbVie Vs. Novartis: Which Has The Technical Edge Before Q4 Earnings?
AbbVie and Novartis to report Q4 earnings. AbbVie in stagnating trend, Novartis bullish. Breakdown of technical charts. Novartis has advantage, investors watch for post-earnings movement. 
Via Benzinga
RFK Jr. And Big Pharma: Health Secretary Hopeful Answers Pointed Questions On Drugs, Insurance, Trump Exec Orders
Kennedy seeks to be Secretary of Health and Human Services — a position that would put him in charge of the health of the American people. 
Via Benzinga
Topics Government
Exposures Political
I Own 4 High-Yield Dividend Stocks. Here's Why I Own Each One.
Via The Motley Fool
Why AbbVie Stock Popped While the Market Flopped on Monday
Via The Motley Fool
AbbVie Builds Momentum With Immunology Growth, Goldman Remains Positive
AbbVie plans to release Q4 2024 results on Jan. 31. Analysts predict $14.8 billion in sales, $2.10 EPS. Immunology growth remains a key focus for investors. 
Via Benzinga
Biotech And Healthcare Stocks Poised For Gains Ahead
The XLV bounced off the bottom this month up 4% to the $144 level led by biopharma and medtech. 
Via Talk Markets
Topics ETFs Stocks / Equities
Is AbbVie Stock a Buy?
Although AbbVie has lost patent exclusivity for its flagship drug, Humira, the company may soon be bigger and better. 
Via The Motley Fool
Topics Intellectual Property
Exposures Intellectual Property
Got $1,500? 3 Healthcare Stocks to Buy and Hold Forever
Via The Motley Fool
Evolus, An AbbVie And Botox Rival, Just Hit The Stratosphere — Here's Why
The company expects to soon expand from a single-product player to a "multi-product innovator." 
Via Investor's Business Daily
Got $500? 2 Pharmaceutical Stocks to Buy and Hold Forever
Via The Motley Fool
3 Unstoppable Dividend-Growth Stocks Yielding More Than 3% That Income-Seeking Investors Want to Buy in 2025 and Hold Forever
Via The Motley Fool
Healthcare And Biotech Stocks Lag The Market Again
Biotech stocks got little help from the JPM Conference despite some recovery to the general market. 
Via Talk Markets
Topics Stocks / Equities
Deal Dispatch: Biden Punts TikTok Ban To Trump, Plus Another Legacy Retailer Goes Bankrupt
Deal opportunities abound: KKR & Co.'s stake in Maya; DuPont's electronics business; Ingevity's North Charleston site; and S&W Seed Company. 
Via Benzinga
Topics Government
Exposures Political
Popular Ozempic, Wegovy Selected For Next Round Of Medicare Drug Price Negotiations
HHS adds 15 drugs to Medicare Part D price negotiations, targeting cost reductions under the Inflation Reduction Act. New prices aim to save billions by 2027. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Top Research Reports For Visa, AbbVie & Analog Devices
Today's Research Daily features new research reports on 16 major stocks, including Visa Inc., AbbVie Inc., Analog Devices, Inc. (ADI), and a micro-cap stock Precipio, Inc. 
Via Talk Markets
Topics Stocks / Equities
< Previous 1 2 3 4 5 6 7 8 9
...
76 77 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.